Form 4 Intra-Cellular Therapies For: Jun 23 Filed by: RIGGS RORY B
Intra-Cellular Therapies Inc. (ITCI)
Last intra-cellular therapies inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intracellulartherapies.com/investor-relations
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
ITCI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ITCI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ITCI alerts
High impacting Intra-Cellular Therapies Inc. news events
Weekly update
A roundup of the hottest topics
ITCI
News
- Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology CongressGlobeNewswire
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $130.00 price target on the stock.MarketBeat
- Intra-Cellular Therapies (NASDAQ:ITCI) delivers shareholders fantastic 54% CAGR over 5 years, surging 3.9% in the last week alone [Yahoo! Finance]Yahoo! Finance
- Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $92.00 price target on the stock, up previously from $68.00.MarketBeat
ITCI
Earnings
- 8/7/24 - Beat
ITCI
Sec Filings
- 9/6/24 - Form 144
- 8/30/24 - Form 4
- 8/30/24 - Form 144
- ITCI's page on the SEC website